Violacein improves recombinant IgG production by controlling the cell cycle of Chinese hamster ovary cells.
Masahide KidoHideaki IdogakiKouji NishikawaTakeshi OmasaPublished in: Cytotechnology (2020)
Chinese hamster ovary (CHO) cells are used as host cells for industrial monoclonal antibody (mAb) production. Cell cycle control is an effective approach to increase mAb production in the cell culture. Violacein, a purple-colored pigment produced by microorganisms, has diverse bioactive properties and has been proposed for various industrial applications. In this study, we evaluated the potency of violacein for cell cycle control and improvement of recombinant immunoglobulin G (IgG) production in CHO cells. Compared with the control, 0.9 μM violacein in a 14-day fed-batch culture increased the maximum IgG concentration by 37.6% via increasing the specific production rate and cell longevity. Cell cycle analysis showed that violacein induced G1 and G2/M phase arrest. However, the G1 arrest was observed only on day 1, while G2/M arrest lasted more than 3 days, suggesting that G2/M arrest mediated the violacein-induced enhanced IgG production. Moreover, in line with the increased protein expression, the expression levels of IgG mRNA and nutrient metabolic rates were also increased. N-Linked glycosylation and charge variant profiles were barely affected by violacein treatment. Our results indicate that violacein affects the cell cycle of CHO cells and increases IgG production without changing product quality, showing promise as a mAb production enhancer in CHO cells. The study provides insight into violacein utilization in industrial mAb manufacturing and can help develop advanced, effective mAb production technologies using CHO cell cultures.
Keyphrases
- cell cycle
- cell proliferation
- induced apoptosis
- cell cycle arrest
- monoclonal antibody
- endoplasmic reticulum stress
- single cell
- cell death
- risk assessment
- heavy metals
- machine learning
- transcription factor
- cell free
- deep learning
- bone marrow
- mesenchymal stem cells
- endothelial cells
- combination therapy
- replacement therapy
- drosophila melanogaster